Results 251 to 260 of about 9,706,348 (372)

Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug.
Amanda L. Stapleton   +10 more
wiley   +1 more source

REPORT ON THE DISEASES OF THE EAR [PDF]

open access: green, 1884
Laurence Turnbull
openalex   +1 more source

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation.
Margaux Petitjean   +16 more
wiley   +1 more source

MiR‐221‐3p Attenuates IL‐33‐Induced Mast Cell Cytokine Expression by Targeting KIT

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Mast cells (MCs) are involved in type 2 inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP), which depends on interleukin (IL)‐33 stimulation. MiR‐221 is reported to be an important regulator of MCs, and miR‐221‐3p can be expressed in CRSwNP. However, the role of miR‐221‐3p in CRSwNP is unclear. Methods Ethmoid tissues
Ruowu Liu   +11 more
wiley   +1 more source

Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts patients’ quality of life (QoL). Standard treatments include nasal irrigations, nasal steroids, systemic corticosteroids, and functional endoscopic sinus surgery (FESS).
Anne‐Sophie Homøe   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy